Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma

In ALK-positive anaplastic large cell lymphoma (ALK+ALCL), a small subset of cancer stem-like (or RR) cells characterized by high Myc expression have been identified. We hypothesize that NPM-ALK contributes to their high Myc expression. While transfection of NPM-ALK into HEK293 cells effectively increased Myc by inhibiting its proteosomal degradation (PD-Myc), this effect was dramatically attenuated when the full-length NPM1 (FL-NPM1) was downregulated using shRNA, highlighting the importance of the NPM-ALK:FL-ALK heterodimers in this context. Consistent with this concept, immunoprecipitation experiments showed that the heterodimers are abundant only in RR cells, in which the half-life of Myc is substantially longer than the bulk cells. Fbw7γ, a key player in PD-Myc, is sequestered by the heterodimers in RR cells, and this finding correlates with a Myc phosphorylation pattern indicative of ineffective PD-Myc. Using confocal microscopy and immunofluorescence staining, we found that the fusion signal between ALK and FL-NPM1, characteristic of the heterodimers, correlates with the Myc level in ALK+ALCL cells from cell lines and patient samples. To conclude, our findings have revealed a novel oncogenic function of NPM-ALK in the nucleus. Specifically, the NPM-ALK:FL-NPM1 heterodimers increase cancer stemness by blocking PD-Myc and promoting Myc accumulation in the cancer stem-like cell subset.

[1]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[2]  P. Limonta,et al.  Cancer Stem Cells—Key Players in Tumor Relapse , 2021, Cancers.

[3]  F. Meggetto,et al.  NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target , 2021, Cancers.

[4]  R. Lai,et al.  Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent , 2021, Cancers.

[5]  P. Ma,et al.  Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy , 2019, Journal of Hematology & Oncology.

[6]  L. Medeiros,et al.  MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients , 2019, Blood.

[7]  C. Mullighan,et al.  Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL , 2019, Blood.

[8]  S. Turner,et al.  NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma , 2019, Cancers.

[9]  G. J. Yoshida Emerging roles of Myc in stem cell biology and novel tumor therapies , 2018, Journal of Experimental & Clinical Cancer Research.

[10]  R. Lai,et al.  Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma , 2018, BMC Cancer.

[11]  T. S. Ramasamy,et al.  Cancer stem cells as key drivers of tumour progression , 2018, Journal of Biomedical Science.

[12]  Š. Pospíšilová,et al.  The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability , 2018, Cancers.

[13]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[14]  L. Michaux,et al.  Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene , 2017, Haematologica.

[15]  L. Vitagliano,et al.  Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ , 2017, Oncogenesis.

[16]  W. Chan,et al.  Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma. , 2017, Cancer cell.

[17]  Dachuan Huang,et al.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. , 2017, Blood.

[18]  M. Wasik,et al.  Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. , 2017, Blood.

[19]  L. Fagnocchi,et al.  Multiple Roles of MYC in Integrating Regulatory Networks of Pluripotent Stem Cells , 2017, Front. Cell Dev. Biol..

[20]  N. Kneteman,et al.  A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma , 2016, Journal of Hematology & Oncology.

[21]  S. Turner,et al.  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency , 2016, Oncogene.

[22]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[23]  P. Wang,et al.  NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair , 2015, Blood Cancer Journal.

[24]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[25]  K. Elenitoba-Johnson,et al.  Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. , 2013, Blood.

[26]  C. Dang MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[27]  L. Meltesen,et al.  Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma , 2013, Journal of pediatric hematology/oncology.

[28]  S. R. Hann,et al.  Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription , 2013, Oncogene.

[29]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[30]  David E. Muench,et al.  c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.

[31]  M. Hitt,et al.  Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma , 2012, Blood Cancer Journal.

[32]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[33]  Y. Hoki,et al.  Crucial Role of C‐Myc in the Generation of Induced Pluripotent Stem Cells , 2011, Stem cells.

[34]  G. Delsol,et al.  Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination , 2011, Blood cancer journal.

[35]  B. Clurman,et al.  Nucleolar Targeting of the Fbw7 Ubiquitin Ligase by a Pseudosubstrate and Glycogen Synthase Kinase 3 , 2011, Molecular and Cellular Biology.

[36]  M. Freedman,et al.  Chromosome 8q24-Associated Cancers and MYC. , 2010, Genes & cancer.

[37]  David N. Boone,et al.  Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation , 2008, Proceedings of the National Academy of Sciences.

[38]  P. Pelicci,et al.  Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ , 2008, The Journal of cell biology.

[39]  G. Delsol,et al.  Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas , 2008, Oncogene.

[40]  L. Armengol,et al.  Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility , 2008, BMC Genomics.

[41]  R. Lai,et al.  Pathobiology of ALK+ anaplastic large-cell lymphoma. , 2007, Blood.

[42]  S. Cook,et al.  The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. , 2007, Cellular signalling.

[43]  S. Monaco,et al.  Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phase , 2007, American journal of hematology.

[44]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[45]  D. Gilliland,et al.  Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling. , 2004 .

[46]  B. Clurman,et al.  A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size , 2004, Current Biology.

[47]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[48]  R. Sears The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.

[49]  J. Griffin,et al.  NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. , 2004, Blood.

[50]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[51]  G. Delsol,et al.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. , 2003, Blood.

[52]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[53]  S. Pittaluga,et al.  Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. , 1996, Blood.

[54]  R. Eisenman,et al.  Expression of the c-myc proto-oncogene during development of Xenopus laevis , 1986, Molecular and cellular biology.

[55]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[56]  A. Rosenwald,et al.  Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. , 2015, Blood.

[57]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.